|NASDAQ: ALBO||Healthcare / Biotechnology / USA|
|44.15||-0.1000||-0.23%||Vol 1.24M||1Y Perf 64.99%|
|Mar 2nd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||58.00||Analyst Rating||Moderate Buy 2.43|
|Potential %||-||Finscreener Ranking||★+ 42.64|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 43.94|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 48.58|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||0.00||Earnings Rating||Sell|
|Market Cap||915.85M||Earnings Date||7th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.80|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||508.02K|
|Avg. Monthly Volume||537.74K|
|Avg. Quarterly Volume||479.79K|
Albireo Pharma Inc. (NASDAQ: ALBO) stock closed at 44.15 per share at the end of the most recent trading day (a -0.23% change compared to the prior day closing price) with a volume of 1.24M shares and market capitalization of 915.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Albireo Pharma Inc. CEO is Ronald H.W. Cooper.
The one-year performance of Albireo Pharma Inc. stock is 64.99%, while year-to-date (YTD) performance is 104.3%. ALBO stock has a five-year performance of 35.55%. Its 52-week range is between 16.02 and 45.23, which gives ALBO stock a 52-week price range ratio of %
Albireo Pharma Inc. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 4.72, a price-to-sale (PS) ratio of 36.50, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.83%, a ROC of -84.98% and a ROE of -103.26%. The company’s profit margin is -80.90%, its EBITDA margin is -214.50%, and its revenue ttm is $24.87 Million , which makes it $1.20 revenue per share.
Of the last four earnings reports from Albireo Pharma Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.80 for the next earnings report. Albireo Pharma Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Albireo Pharma Inc. is Moderate Buy (2.43), with a target price of $58, which is 0.00% compared to the current price. The earnings rating for Albireo Pharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Albireo Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Albireo Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.79, ATR14 : 0.67, CCI20 : 40.16, Chaikin Money Flow : -0.19, MACD : 1.28, Money Flow Index : 21.90, ROC : -0.09, RSI : 68.04, STOCH (14,3) : 52.98, STOCH RSI : 0.05, UO : 45.73, Williams %R : -47.02), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Albireo Pharma Inc. in the last 12-months were: Jan P. Mattsson (Sold 3 892 shares of value $159 481 ), Jason G. Duncan (Sold 3 134 shares of value $101 591 ), Martha Carter (Sold 1 371 shares of value $54 481 ), Michelle Graham (Sold 2 189 shares of value $90 396 ), Pamela Stephenson (Sold 3 564 shares of value $116 947 ), Ronald H.W. Cooper (Sold 3 812 shares of value $117 241 ), Simon Nicolas Reade Harford (Sold 2 462 shares of value $97 916 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Strong Buy|
Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.
CEO: Ronald H.W. Cooper
Telephone: +1 857 254-5555
Address: 10 Post Office Square, South Boston 02109, MA, US
Number of employees: 90
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.